Compare Advanced Micro Devices (AMD) vs Amgen, Inc. (AMGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advanced Micro Devices vs Amgen, Inc. — how do they compare? Advanced Micro Devices trades at $534.33 (market cap $909.70B), while Amgen, Inc. trades at $360.83 (market cap $196.12B). The key difference: Advanced Micro Devices is far larger — about 4.6× Amgen, Inc.'s market cap, and Amgen, Inc. pays a 2.77% dividend while Advanced Micro Devices pays none. Which is the better fit depends on your goals.
| AMD | AMGN | |
|---|---|---|
Market Cap | $909.70B | $196.12B |
Sector | Technology | Health |
52-Week High | $580.91 | $388.16 |
52-Week Low | $146.24 | $271.18 |
Enterprise Value | $901.22B | $241.41B |
Dividend Yield | — | 2.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMD trades at $557.89, up 2.04% today and near its 52-week high, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth, with 2025 revenue reaching $34.64 billion and net income surging to $4.34 billion, though valuation ratios like P/E of 185.96 indicate premium pricing. Recent earnings beats and positive AI-driven news fuel investor optimism.
Outlook remains positive due to AI demand and earnings momentum, but high valuations and intense competition pose risks. Analyst consensus is strongly bullish with a $508.24 price target, though the stock trades above this, suggesting near-term caution amid long-term growth potential.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Advanced Micro Devices
Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.
Read more on AMD →About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →
